Schonfeld Strategic Advisors LLC

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1665241 NEW YORK, NY

Position in PTGX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$3,441,065

-$2,882,406 QoQ

Shares Held

28,072

-70.5% QoQ

Ownership

0.043%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

#116

of 341 holders

Holding Since

Jun 2021

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names. PTGX ranks #33 (0.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INBX	Inhibrx Biosciences, Inc.	697,586	$66,096,273
2	AGIO	Agios Pharmaceuticals, Inc.	520,083	$19,300,280
3	JAZZ	Jazz Pharmaceuticals plc	77,272	$18,620,233
4	VRDN	Viridian Therapeutics, Inc.\DE	793,508	$14,576,741
5	MBX	MBX Biosciences, Inc.	248,670	$13,726,584
6	XENE	Xenon Pharmaceuticals Inc.	227,330	$13,721,638
7	PTCT	Ptc Therapeutics, Inc.	147,425	$12,025,457
8	INSM	INSMED Inc	104,378	$11,128,782

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,441,065	28,072	-70.5%	Shares	Sole	2026-08-14
2025-09-30	$6,323,471	95,190	+23.5%	Shares	Sole	2025-11-14
2025-06-30	$4,259,548	77,068	-73.2%	Shares	Sole	2025-08-14
2025-03-31	$13,893,876	287,301	+370.8%	Shares	Sole	2025-05-15
2024-09-30	$2,746,170	61,026	+24.4%	Shares	Sole	2024-11-14
2024-06-30	$1,700,067	49,064	-44.9%	Shares	Sole	2024-08-14
2023-12-31	$2,043,361	89,113	-42.2%	Shares	Sole	2024-02-14
2023-09-30	$2,570,354	154,098	+3.4%	Shares	Sole	2023-11-14
2023-03-31	$3,426,816	148,992	+368.3%	Shares	Sole	2023-05-15
2022-09-30	$268,192	31,814	-33.8%	Shares	Sole	2022-11-14
2022-06-30	$379,933	48,032	+250.6%	Shares	Sole	2022-08-15
2022-03-31	$324,416	13,700	+174.0%	Shares	Sole	2022-05-16
2021-06-30	$224,400	5,000	—	Shares	Sole	2021-11-16
No filing history on record for this holder in this stock.